Literature DB >> 25333211

Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy.

S Salvatore1, R E Nappi, M Parma, R Chionna, F Lagona, N Zerbinati, S Ferrero, M Origoni, M Candiani, U Leone Roberti Maggiore.   

Abstract

OBJECTIVE: To investigate the effects of fractional microablative CO2 laser on sexual function and overall satisfaction with sexual life in postmenopausal women with vulvovaginal atrophy (VVA).
METHOD: This prospective study included 77 postmenopausal women (mean age 60.6 ± 6.2 years) treated for VVA symptoms with the fractional microablative CO2 laser system (SmartXide(2) V(2)LR, Monalisa Touch, DEKA, Florence, Italy). Sexual function and quality of life were evaluated with the Female Sexual Function Index (FSFI) and the Short Form 12 (SF-12), respectively, both at baseline and at 12-week follow-up. A 10-mm visual analog scale was used to measure the overall satisfaction with sexual life and the intensity of VVA symptoms (vaginal burning, vaginal itching, vaginal dryness, dyspareunia and dysuria) before and after the study period.
RESULTS: We observed a significant improvement in the total score and the scores in each specific domain of the FSFI at 12-week follow-up compared to baseline (p < 0.001). After concluding the laser treatment, the overall satisfaction with sexual life significantly improved (p < 0.001). Seventeen (85%) out of 20 (26%) women, not sexually active because of VVA severity at baseline, regained a normal sexual life at the 12-week follow-up. Finally, we also found a significant improvement in each VVA symptom (p < 0.001) and in quality-of-life evaluation, both for the scores in the physical (p = 0.013) and mental (p = 0.002) domains.
CONCLUSIONS: Fractional microablative CO2 laser treatment is associated with a significant improvement of sexual function and satisfaction with sexual life in postmenopausal women with VVA symptoms.

Entities:  

Keywords:  DYSPAREUNIA; FRACTIONAL CO2 LASER; MENOPAUSE; SEXUAL FUNCTION; SEXUAL INTERCOURSE; VAGINAL DRYNESS; VULVOVAGINAL ATROPHY

Mesh:

Year:  2014        PMID: 25333211     DOI: 10.3109/13697137.2014.975197

Source DB:  PubMed          Journal:  Climacteric        ISSN: 1369-7137            Impact factor:   3.005


  29 in total

1.  Microablative fractional CO2 laser for the genitourinary syndrome of menopause: power of 30 or 40 W?

Authors:  Eleni Pitsouni; Themos Grigoriadis; Matthew Falagas; Angeliki Tsiveleka; Stefano Salvatore; Stavros Athanasiou
Journal:  Lasers Med Sci       Date:  2017-08-02       Impact factor: 3.161

Review 2.  Female Sexual Function at Midlife and Beyond.

Authors:  Holly N Thomas; Genevieve S Neal-Perry; Rachel Hess
Journal:  Obstet Gynecol Clin North Am       Date:  2018-10-25       Impact factor: 2.844

3.  Comments on Singh et al.: Laser vaginal rejuvenation: not ready for prime time.

Authors:  Umberto Leone Roberti Maggiore; Massimo Candiani; Stefano Salvatore
Journal:  Int Urogynecol J       Date:  2015-03-27       Impact factor: 2.894

Review 4.  Laser therapy as a treatment modality for genitourinary syndrome of menopause: a critical appraisal of evidence.

Authors:  Angamuthu Arunkalaivanan; Hervinder Kaur; Oseka Onuma
Journal:  Int Urogynecol J       Date:  2017-02-02       Impact factor: 2.894

Review 5.  Laser Therapy for Genitourinary Syndrome of Menopause.

Authors:  Andrew Rabley; Tina O'Shea; Russell Terry; Sharon Byun; M Louis Moy
Journal:  Curr Urol Rep       Date:  2018-08-17       Impact factor: 3.092

6.  Management of Potential Long-Term Toxicities in Breast Cancer Patients.

Authors:  C C O'Sullivan; K J Ruddy
Journal:  Curr Breast Cancer Rep       Date:  2016-10-13

7.  An international Urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for the assessment of sexual health of women with pelvic floor dysfunction.

Authors:  Rebecca G Rogers; Rachel N Pauls; Ranee Thakar; Melanie Morin; Annette Kuhn; Eckhard Petri; Brigitte Fatton; Kristene Whitmore; Sheryl A Kingsberg; Joseph Lee
Journal:  Int Urogynecol J       Date:  2018-03-26       Impact factor: 2.894

Review 8.  A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.

Authors:  Mariana S Sousa; Michelle Peate; Sherin Jarvis; Martha Hickey; Michael Friedlander
Journal:  Ther Adv Med Oncol       Date:  2017-01-31       Impact factor: 8.168

Review 9.  Physical examination of the female cancer patient with sexual concerns: What oncologists and patients should expect from consultation with a specialist.

Authors:  Stacy Tessler Lindau; Emily M Abramsohn; Shirley R Baron; Judith Florendo; Hope K Haefner; Anuja Jhingran; Vanessa Kennedy; Mukta K Krane; David M Kushner; Jennifer McComb; Diane F Merritt; Julie E Park; Amy Siston; Margaret Straub; Lauren Streicher
Journal:  CA Cancer J Clin       Date:  2016-01-19       Impact factor: 508.702

Review 10.  Vaginal Health During Breast Cancer Treatment.

Authors:  Sandy J Falk; Sharon Bober
Journal:  Curr Oncol Rep       Date:  2016-05       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.